

## RESEARCH ARTICLE

# Exploration of Molecular Mechanisms of Diffuse Large B-cell Lymphoma Development Using a Microarray

Zong-Xin Zhang, Cui-Fen Shen, Wei-Hua Zou, Li-Hong Shou, Hui-Ying Zhang, Wen-Jun Jin\*

### Abstract

**Objective:** We aimed to identify key genes, pathways and function modules in the development of diffuse large B-cell lymphoma (DLBCL) with microarray data and interaction network analysis. **Methods:** Microarray data sets for 7 DLBCL samples and 7 normal controls was downloaded from the Gene Expression Omnibus (GEO) database and differentially expressed genes (DEGs) were identified with Student's t-test. KEGG functional enrichment analysis was performed to uncover their biological functions. Three global networks were established for immune system, signaling molecules and interactions and cancer genes. The DEGs were compared with the networks to observe their distributions and determine important key genes, pathways and modules. **Results:** A total of 945 DEGs were obtained, 272 up-regulated and 673 down-regulated. KEGG analysis revealed that two groups of pathways were significantly enriched: immune function and signaling molecules and interactions. Following interaction network analysis further confirmed the association of DEGs in immune system, signaling molecules and interactions and cancer genes. **Conclusions:** Our study could systemically characterize gene expression changes in DLBCL with microarray technology. A range of key genes, pathways and function modules were revealed. Utility in diagnosis and treatment may be expected with further focused research.

**Keywords:** Diffuse large B-cell lymphoma (DLBCL) - differentially expressed genes - pathway - module

*Asian Pacific J Cancer Prev*, 14 (3), 1731-1735

### Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma. According to statistics, DLBCL accounts for about 3% of primary brain tumors (Davis et al., 1999) and 30% - 40% of adult non-Hodgkin's malignant lymphoma (Kawano et al., 2004). It can be originated from lymph nodes or extranodal organs and tissues, and transformed from the inert lymphoma. It has a high recurrence rate about 35% - 60% in 1-2 years and a low survival rate as the 5-year survival rate is only 20% - 40%. In the last few decades, incidence of DLBCL exhibits an increasing trend. Therefore, developing effective treatments is an urgent task (Akbulut, 2012).

Previous studies have reported abnormalities in multiple biological pathways that involved in the pathogenesis of DLBCL, such as chemotactic factor signaling pathways (Smith et al., 2007), NF $\kappa$ B signaling pathway (Montesinos-Rongen et al., 2012), host inflammatory response (Monti et al., 2005) and chronic active B-cell-receptor signaling (Davis et al., 2010). Lenz et al report oncogenic CARD11 mutations in DLBCL and consider that it can be a target for therapy (Lenz et al., 2008). Yao et al find that expression of dendritic cell marker CD21 is a positive prognostic factor for DLBCL (Yao et al., 2012). Expression of B-cell CLL/lymphoma 6

(BCL6) and BCL2 is also thought to be able to predicting survival in patients with DLBCL (Lossos et al., 2001; Iqbal et al., 2006). However, so far, the pathogenesis of DLBCL is not yet entirely clear.

In present study, microarray technology was adopted to globally characterize the changes in gene expression. Then interaction network analysis was conducted to identify key genes, pathways and modules, which would be beneficial to elucidate the mechanisms of DLBCL.

### Materials and Methods

#### Microarray data

Microarray data set GSE25297 (Sung et al., 2011) was downloaded from GEO database (<http://www.ncbi.nlm.nih.gov/geo/>), including 7 DLBCL samples and 7 normal controls. Raw data was collected with Agilent-014850 Whole Human Genome Microarray 4x44K G4112F. Probe annotation was also provided by Agilent.

Following steps were done to process the raw data: (1) Agilent Feature Extraction Software (v9) was used to extract DNA hybridization signals; (2) VSN normalization was performed and expression levels were determined; (3) probes linked with more than one gene were removed; (4) multiple probes pointing to the same genes were averaged. Finally, expression profiling data with 14 samples and

Department of Laboratory, Huzhou Central Hospital, Huzhou, Zhejiang, China \*For correspondence: [jinwenjunwwjj@hotmail.com](mailto:jinwenjunwwjj@hotmail.com)

**Table 1. Enriched KEGG Pathways for the 945 DEGs**

Term	p value	Bonferroni
hsa04640:Hematopoietic cell lineage	8.30E-07	1.25E-04
hsa04514:Cell adhesion molecules (CAMs)	1.08E-05	0.001635
hsa04510:Focal adhesion	1.57E-05	0.00237
hsa04060:Cytokine-cytokine receptor interaction	4.75E-05	0.007147
hsa04660:T cell receptor signaling pathway	2.91E-04	0.042989

Note: Bonferroni is the corrected p value with BH method

18,459 genes were obtained.

#### Screening of differentially expressed genes

Microarray data for DLBCL were compared with that for control to identify DEGs using Student's t-test. Multiple-correction was conducted for the p value with Benjamin & Hochberg (BH) method to reduce false positive.  $FDR \leq 0.1$  and fold change  $\geq 2$  were set as the cut-off.

#### Functional enrichment analysis

KEGG annotation is useful in exploring the biological functions of the DEGs. The EASE that developed by DAVID (Huang da et al., 2009) was chosen to complete this task, and it is similar to Fisher's exact test. EASE of 0.1 was selected as the threshold.

#### Establishment of global network for immune system


Global network for immune system-related pathways was established to observe the distribution of the DEGs implicated in immune. 15 relevant pathways were acquired from the KEGG pathway database: hematopoietic cell lineage, complement and coagulation cascades, toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, cytosolic DNA-sensing pathway, natural killer cell mediated cytotoxicity, antigen processing and presentation, T cell receptor signaling pathway, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, leukocyte transendothelial migration, intestinal immune network for IgA production and chemokine signaling pathway. Then they were transformed into undirected graph, where genes were nodes and interactions were represented as lines. All the graphs were combined and duplicate were removed. Finally, the global network for immune system was generated.

#### Establishment of global network for signaling molecule interactions

A global network was built up for signaling molecule interactions to investigate the distribution of the relevant DEGs. Following pathways were obtained from KEGG: neuroactive ligand-receptor interaction, Cytokine-cytokine receptor interaction, ECM-receptor interaction and cell adhesion molecules (CAMs). Then the network was completed according to the method mentioned above.

#### Establishment of global network for oncogenes

An oncogenes-based global network was set up to understand the distribution of relevant DEGs. 14 cancer-related pathways were acquired from KEGG: colorectal cancer, pancreatic cancer, glioma, thyroid cancer, acute



**Figure 1. The Global Network for Immune System.** Up-regulated genes are shown in red while down-regulated genes are in blue. A: the distribution of the 55 relevant DEGs in the global network. B: the network comprised of genes interacting with the 55 DEGs

myeloid leukemia, chronic myeloid leukemia, basal cell carcinoma, melanoma, renal cell carcinoma, bladder cancer, prostate cancer, endometrial cancer, small cell lung cancer and non-small cell lung cancer. Then the network was completed according to the method mentioned above.

## Results

#### Differentially expressed genes

DEGs were identified with Student's t-test and the p values were corrected by BH method. The corrected  $FDR < 0.05$  and fold change  $> 2$  were set as the cut-offs. A total of 945 DEGs were obtained, including 272 up-regulated genes and 673 down-regulated genes, and the ratio was 1:2.47. More DEGs were down-regulated. These DEGs might play key roles in the development of DLBCL and thus further analysis was performed.


#### KEGG functional enrichment analysis results

KEGG functional enrichment analysis was conducted and p values were corrected with BH method. A total of 18 pathway were revealed as  $p$  value  $< 0.05$ , and 5 remained significant after multiple correction as  $FDR \leq 0.05$  (Table 1).


The five pathways could be divided into two groups. The first group was associated with immune system: hematopoietic cell lineage and T cell receptor signaling pathway. The second group was about signaling molecules & interactions: cell adhesion molecules (CAMs) and cytokine-cytokine receptor interaction. These pathways might play important parts in the incidence and progression of DLBCL. Previous studies have reported the close relationships between chemokine as well as chemokine receptor and metastasis of several cancers (Kakinuma and Hwang, 2006; Koizumi et al., 2007). Besides, chemokine CXCL12-CXCR4 is found to be implicated in the crosstalk between central nervous system and immune system (Klein and Rubin, 2004).

#### DEGs and immune system

As shown in KEGG pathway enrichment analysis, some DEGs were significantly enriched in immune system-related pathways, thus a global network about



**Figure 2. Two Modules Containing Several DEGs were Extracted from the Global Network.** Down-regulated genes were in blue and up-regulated genes red



**Figure 3. The Global Network for Signaling Molecules & Interactions.** Up-regulated genes are shown in red and down-regulated genes blue. A: the distribution of the 53 DEGs in the global network. B: the network comprised of genes interacting with the 53 DEGs


immune system was built up to systemically screen key genes, such as hub genes or functional modules, which play important parts in the pathogenesis of DLBCL. A network including 657 genes and 3611 interactions were obtained (Figure 1), among which 55 were found to be DEGs with annotations, 51 down-regulated and 3 up-regulated. Most of the DEGs were down-regulated, suggesting decline in immune function.

Figure 1 A showed the distribution of the 55 DEGs in the global network. The DEGs were almost located in the center of the network, suggesting their important regulatory roles and influence on the immune function. Then the degree for each DEG was calculated and the top 10 were determined: PIK3CD (66), PIK3R5 (66), HLA-G (25), CLDN14 (21), CLDN15 (21), CLDN5 (21), VCAM1 (19), CCL14 (18), CCL19 (18) and CCL21 (18).


Genes interacting with the 55 DEGs were extracted separately (Figure 1 B) and several modules were observed, such as the one containing CLDN14 (21), CLDN15 (21) and CLDN5 (21) (Figure 2 A), and another one with CCL14 (18), CCL19 (18) and CCL21 (18) etc. (Figure 2 B). The modules may present certain biological functions and thus were analyzed further.

#### DEGs and signaling molecules & interactions

Another group of pathways enriched in DEGs was signaling molecules & interactions. Therefore, a global network was generated to identify key genes closely associated with DLBCL. The global network was



**Figure 4. The Global Network for Cancer Genes.** Up-regulated genes are shown in red and down-regulated genes blue. A: the distribution of the 29 DEGs in the global network. B: the network comprised of genes interacting with the 29 DEGs



**Figure 5. The Networks Comprised of Genes Interacting with the 29 DEGs.** A: the network comprised of genes interacting with DEGs involved in signaling molecules & interactions. B: the network comprised of genes interacting with DEGs involved in immune system. Up-regulated genes are shown in red and down-regulated genes blue

comprised of 389 genes and 1071 interactions, and a total of 53 DEGs were included, 44 down-regulated and 9 up-regulated (Figure 3). Most of the genes were down-regulated, implying the decreased activity in cell communication.

Figure 3 A shows the distribution of the 53 DEGs in the global network. The top 11 genes with most degree were ITGA3 (36), ITGA9 (35), SDC1 (27), CLDN14 (19), CLDN15 (19), CLDN5 (19), COL4A1 (15), COL4A2 (15), COL4A (15), COL5A3 (15) and COL6A2 (15). Two modules were observed in Figure 3 B: one with CLDN15 (19), CLDN5 (19) and COL4A1 (15), and another one with CD4.

#### DEGs and global network for cancer genes

A global network for cancer genes was established to investigate the involvement of the DEGs in DLBCL. The global network was comprised of 332 genes and 1481 interactions (Figure 4). 29 had annotations in this network, 23 down-regulated and 6 up-regulated. Most of the cancer-related DEGs were down-regulated.

Figure 4 A shows the distribution of the 29 DEGs in the global network. The top 11 genes with most degree were PDGFRB (46), PIK3CD (31), PIK3R5 (29), FZD10 (22), CCND1 (18), ITGA3 (18), FLT3 (14), IGF1 (9), SHC1 (7), COL4A1 (6), COL4A2 (6) and COL4A4 (6). PDGFRB had the maximum degree and it was a platelet-derived growth factor (Bornfeldt et al., 1995). Previous study indicates that it is related with glioma and lower level was observed in glioma with high grade malignancy (Lokker et al., 2002). It interacts with PIK3CD and PIK3R5. The

results of the present study indicate that PDGF-D promotes malignant mesothelioma cell chemotaxis through PDGF- $\beta\beta$  receptor signaling pathways along a PI3 kinase/PDK1/Akt/Rac1/ROCK axis and relevant to ERK activation.

Then DEGs observed in the above two networks were entered into this network and distribution was shown in Figure 5.

As shown in Figure 5, some of the DEGs related with immune and signaling molecules & interactions interacted with cancer genes. These genes were located in part of the network, rather than the whole, in accordance with the knowledge that cancer is caused by multiple factors. The DEGs shared by both networks of signaling molecules & interactions and cancer genes were ITGA3, LAMB2, COL4A1, LAMC2, COL4A2, COL4A2, LAMC3, FLT3, VEGFC and TGFBR2, most of which were laminin and matrix membrane collagen. And those for networks of immune system and cancer genes were PTPN11, SOS1, PIK3R5, PIK3CD, SHC1 and PAK6, most of which were phosphatidylinositol and tyrosine kinase.

## Discussion

Gene expression data for DLBCL was compared with that for normal control to identify DEGs. Then their biological functions were investigated by KEGG functional enrichment analysis and two groups of pathways were revealed. The first one was immune function-related pathways, such as hematopoietic cell lineage and cell receptor signaling pathway, and the second one was signaling molecules & interactions, such as cell adhesion molecules and cytokine-cytokine receptor interaction. Thus we considered that abnormalities in immune function and signaling molecules & interactions were major causes of DLBCL.

Some key genes were identified with network analysis. These genes had the highest degree and thus imposed significant impact on the whole network. Perturbations in these genes might contribute most to the incidence of DLBCL.

The DEGs like PIK3CD, PIK3R5, HLA-G, CLDN14, CLDN15, CLDN5, VCAM1, CCL14, CCL19 and CCL21 were found to be linked with immune function. Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PIK3CD) and phosphoinositide-3-kinase, regulatory subunit 5 (PIK3R5) belong to PIK3 family, which is found to be involved in tumor growth (Katso et al., 2001; Koutros et al., 2010) and metastasis (Wee et al., 2008). Therefore, we considered that these hub genes might play critical roles in the development of DLBCL. Courtney et al think that the PI3K pathway can be drug target for cancer (Courtney et al., 2010). Major histocompatibility complex class I G (HLA-G) belongs to the HLA class I heavy chain paralogues. It is suspected to provide an escape mechanism for cancer cells (Davidson et al., 2005; Rouas-Freiss et al., 2005). In addition, two modules were extracted from the immune system-related network. Most of the genes in the first module (Figure 2 A) were claudins, a class of membrane proteins participating in tight junctions. They were

implicated in signal transduction and maintenance of cell polarity. Previous studies have indicated that claudins were over-expressed in cancers (Rangel et al., 2003), and even involved in cancer cell metastasis (Dhawan et al., 2005) and invasion processes (Agarwal et al., 2005; Oku et al., 2006; Takehara et al., 2009). Some studies consider that some members of claudins can be targets for treatment (Michl et al., 2001; Morin, 2005). Most of the genes in the second module (Figure 2 B) were chemokines and their receptors. Chemokine (C-C motif) ligand 21 (CCL21) is reported to guide aggregation of B cells in the thyroid gland of transgenic mice (Muniz et al., 2011). Chemokines were also closely linked with cancer cell survival and proliferation (Xu et al., 2011).

DEGs such as ITGA3, ITGA9, SDC 1, CLDN14, CLDN15, CLDN5, COL4A1, COL4A2, COL4A, COL5A3 and COL6A2 were associated with signaling molecules & interactions. Integrin alpha 3 (ITGA3) and integrin alpha 9 (ITGA9) are members of integrin family. Chen et al. report that ITGA3 is implicated in the metastasis and invasion of meningiomas, and its expression level is negatively correlated with proliferative activity and degree of malignancy (Chen et al., 2009). The integrins and corresponding signaling pathways can be drug targets for treatment of cancers (Hannigan et al., 2005; Cai and Chen, 2006; Mitra and Schlaepfer, 2006). Collagen type IV alpha 1 (COL4A1), collagen type IV alpha 2 (COL4A2), collagen type IV alpha (COL4A), collagen type V alpha 3 (COL5A3) and collagen type VI alpha 2 (COL6A2) are various collagen chains, components of basement membrane, which plays an important role in cancer metastasis and invasion (Oikawa et al.). Havenith et al report the prognostic value of type IV collagen in colorectal cancer (Havenith et al., 1988). Two modules were also identified. The first module (Figure 3 B upper) contains CLDN15, CLDN5 and COL4A1 and was associated with signal transduction and maintenance of cell polarity. The second module (Figure 3 B lower) includes CD4 and was linked with inflammatory response. Genes in this module were components of second class of histocompatibility complex and participated in antigen presentation. CD4 was located at the center of the module and found to be down-regulated, implying the decreased capacity of immune system which provides favorable conditions for the formation and growth of cancer cells.

Moreover, several DEGs usually formed a function module, which worked together to finish certain biological process. Alterations in these modules might provide favorable environment for the development of DLBCL.

Some DEGs participating in the networks for immune function and signaling molecules & interactions were also observed in the network for cancer genes, which further confirms their implications in the cancer genesis. The analysis suggested that PIK3CD, PIK3R5 and ITGA3 were in very important positions.

Overall, a range of critical genes, pathways and function modules were revealed in present study, which were really helpful in improving our understandings about the pathogenesis of DLBCL. In addition, more investigations are needed to fulfill their clinical applications.

## References

- Agarwal R, D'Souza T, Morin PJ (2005). Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. *Cancer Res*, **65**, 7378-85.
- Akbulut S (2012). Unusual cause of adult intussusception: diffuse large B-cell non-Hodgkin's lymphoma: a case report and review. *Eur Rev Med Pharmacol Sci*, **16**, 1938.
- Bornfeldt KE, Raines EW, Graves LM, et al (1995). Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. *Ann N Y Acad Sci*, **766**, 416-30.
- Cai W, Chen X (2006). Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. *Anticancer Agents Med Chem*, **6**, 407-28.
- Chen J, Xu X, Wang H (2009). Expression of integrin-alpha(3) mRNA in meningiomas and its correlation with proliferation and invasion. *J Huazhong Univ Sci Technol Med Sci*, **29**, 94-6.
- Courtney KD, Corcoran RB, Engelman JA (2010). The PI3K pathway as drug target in human cancer. *J Clin Oncol*, **28**, 1075-83.
- Davidson B, Elstrand MB, McMaster MT, et al (2005). HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. *Gynecol Oncol*, **96**, 42-7.
- Davis FG, McCarthy BJ, Berger MS (1999). Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. *Neuro Oncol*, **1**, 205-11.
- Davis RE, Ngo VN, Lenz G, et al (2010). Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature*, **463**, 88-92.
- Dhawan P, Singh AB, Deane NG, et al (2005). Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. *J Clin Invest*, **115**, 1765-76.
- Hannigan G, Troussard AA, Dedhar S (2005). Integrin-linked kinase: a cancer therapeutic target unique among its ILK. *Nat Rev Cancer*, **5**, 51-63.
- Havenith MG, Arends JW, Simon R, et al (1988). Type IV collagen immunoreactivity in colorectal cancer. Prognostic value of basement membrane deposition. *Cancer*, **62**, 2207-11.
- Huang da W, Sherman BT, Lempicki RA (2009). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res*, **37**, 1-13.
- Iqbal J, Neppalli VT, Wright G, et al (2006). BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. *J Clin Oncol*, **24**, 961-8.
- Kakinuma T, Hwang ST (2006). Chemokines, chemokine receptors, and cancer metastasis. *J Leukoc Biol*, **79**, 639-51.
- Katso R, Okkenhaug K, Ahmadi K, et al (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. *Annu Rev Cell Dev Biol*, **17**, 615-75.
- Kawano R, Ohshima K, Karube K, et al (2004). Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. *Br J Haematol*, **127**, 305-7.
- Klein RS, Rubin JB (2004). Immune and nervous system CXCL12 and CXCR4: parallel roles in patterning and plasticity. *Trends Immunol*, **25**, 306-14.
- Koizumi K, Hojo S, Akashi T, et al (2007). Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. *Cancer Sci*, **98**, 1652-8.
- Koutros S, Schumacher FR, Hayes RB, et al (2010). Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. *Cancer Res*, **70**, 2389-96.
- Lenz G, Davis RE, Ngo VN, et al (2008). Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. *Science*, **319**, 1676-9.
- Lokker NA, Sullivan CM, Hollenbach SJ, et al (2002). Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. *Cancer Res*, **62**, 3729-35.
- Lossos IS, Jones CD, Warnke R, et al (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. *Blood*, **98**, 945-51.
- Michl P, Buchholz M, Rolke M, et al (2001). Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. *Gastroenterology*, **121**, 678-84.
- Mitra SK, Schlaepfer DD (2006). Integrin-regulated FAK-Src signaling in normal and cancer cells. *Curr Opin Cell Biol*, **18**, 516-23.
- Montesinos-Rongen M, Schafer E, Siebert R, Deckert M Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. *Acta Neuropathol*, **124**, 905-6.
- Monti S, Savage KJ, Kutok JL, et al (2005). Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood*, **105**, 1851-61.
- Morin PJ (2005). Claudin proteins in human cancer: promising new targets for diagnosis and therapy. *Cancer Res*, **65**, 9603-6.
- Muniz LR, Pacer ME, Lira SA, Furtado GC A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. *J Immunol*, **187**, 828-34.
- Oikawa Y, Hansson J, Sasaki T, et al Melanoma cells produce multiple laminin isoforms and strongly migrate on alpha5 laminin(s) via several integrin receptors. *Exp Cell Res*, **317**, 1119-33.
- Oku N, Sasabe E, Ueta E, et al (2006). Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. *Cancer Res*, **66**, 5251-7.
- Rangel LB, Agarwal R, D'Souza T, et al (2003). Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. *Clin Cancer Res*, **9**, 2567-75.
- Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED (2005). HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? *Cancer Res*, **65**, 10139-44.
- Smith JR, Falkenhagen KM, Coupland SE, et al (2007). Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. *Am J Clin Pathol*, **127**, 633-41.
- Sung CO, Kim SC, Karnan S, et al (2011). Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. *Blood*, **117**, 1291-300.
- Takehara M, Nishimura T, Mima S, et al (2009). Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. *Biol Pharm Bull*, **32**, 825-31.
- Wee S, Lengauer C, Wiederschain D (2008). Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. *Curr Opin Oncol*, **20**, 77-82.
- Xu Y, Liu L, Qiu X, et al CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells. *PLoS One*, **6**, e21119.
- Yao WK, Wang YP, Peng F, et al (2012). [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma]. *Zhonghua Bing Li Xue Za Zhi*, **41**, 818-22.